Citations

Showing 10 of 108162 citations.

An ethics framework for consolidating and prioritizing COVID-19 clinical trials
Meyer, Michelle N. , Gelinas, Luke , Hull, Sara Chandros , Magnus, David , Mohapatra, Seema , Sharp, Richard R. , Spector‐Bagdady, Kayte , Wilfond, Benjamin S. , Sugarman, Jeremy , Lynch, Holly Fernandez , Sharp, Richard R , Bierer, Barbara E. , Joffe, Steven

Mayo Clinic

Clinical Trials | February 10, 2021 | Volume: 18 | Issue: 2 | Pages: 226-233

10.1177/1740774520988669 | PMID 33530721 Get It

Given the dearth of established safe and effective interventions to respond to COVID-19, there is an urgent ethical imperative to conduct meaningful clinical research. The good news is that interventions to be tested are not in short supply. Unfortunately, the human and material resources needed to conduct these trials are finite. It is essential that trials be robust and meet enrollment targets and that lower-quality studies not be permitted to displace higher-quality studies, delaying answers to critical questions. Yet, with few exceptions, existing research review bodies and processes are not designed to ensure these conditions are satisfied. To meet this challenge, we offer guidance for research institutions about how to ethically consolidate and prioritize COVID-19 clinical trials, while recognizing that consolidation and prioritization should also take place upstream (among manufacturers and funders) and at a higher level (e.g. nationally). In our proposed three-stage process, trials must first meet threshold criteria. Those that do are evaluated in a second stage to determine whether the institution has sufficient capacity to support all proposed trials. If it does not, the third stage entails evaluating studies against two additional sets of comparative prioritization criteria: those specific to the study and those that aim to advance diversification of an institution’s research portfolio. To implement these criteria fairly, we propose that research institutions form COVID-19 research prioritization committees. We briefly discuss some important attributes of these committees, drawing on the authors’ experiences at our respective institutions. Although we focus on clinical trials of COVID-19 therapeutics, our guidance should prove useful for other kinds of COVID-19 research, as well as non-pandemic research, which can raise similar challenges due to the scarcity of research resources.
Working Agenda for Black Mothers
Bond, Rachel M. , Gaither, Kecia , Nasser, Samar A. , Albert, Michelle A. , Ferdinand, Keith C. , Njoroge, Joyce , Parapid, Biljana , Hayes, Sharonne N. , Pegus, Cheryl , Sogade, Bola, Grodzinsky, Anna , McCullough, Cassandra, Hayes, Sharonne N , Watson, Karol E. , Ofili, Elizabeth

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | February 10, 2021 | Volume: 14 | Issue: 2 | Pages: No page available

10.1161/circoutcomes.120.007643 | PMID 33563007 Get It

Following decades of decline, maternal mortality began to rise in the United States around 1990—a significant departure from the world’s other affluent countries. By 2018, the same could be seen with the maternal mortality rate in the United States at 17.4 maternal deaths per 100 000 live births. When factoring in race/ethnicity, this number was more than double among non-Hispanic Black women who experienced 37.1 maternal deaths per 100 000 live births. More than half of these deaths and near deaths were from preventable causes, with cardiovascular disease being the leading one. In an effort to amplify the magnitude of this epidemic in the United States that disproportionately plagues Black women, on June 13, 2020, the Association of Black Cardiologists hosted the Black Maternal Heart Health Roundtable—a collaborative task force to tackle the maternal health crisis in the Black community. The roundtable brought together diverse stakeholders and champions of maternal health equity to discuss how innovative ideas, solutions and opportunities could be implemented, while exploring additional ways attendees could address maternal health concerns within the health care system. The discussions were intended to lead the charge in reducing maternal morbidity and mortality through advocacy, education, research, and collaborative efforts. The goal of this roundtable was to identify current barriers at the community, patient, and clinician level and expand on the efforts required to coordinate an effective approach to reducing these statistics in the highest risk populations. Collectively, preventable maternal mortality can result from or reflect violations of a variety of human rights—the right to life, the right to freedom from discrimination, and the right to the highest attainable standard of health. This is the first comprehensive statement on this important topic. This position paper will generate further research in disparities of care and promote the interest of others to pursue strategies to mitigate maternal mortality.
A Tale of a Two Waves Epidemic: Characteristics and Mortality Risk Factors for COVID-19 ICU Patients in the French West Indies
Martino, Frédéric , Bleakley, Kevin, Roy, Fabien Van, Valette, Marc, Camous, Laurent , Pommier, Jean‐David , Flurin, Laure , Carlès, Michel

Mayo Clinic

No container title available | February 10, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-200243/v1 Get It

Abstract Introduction Guadeloupe, a French West Indies island, has been fiercely affected by two large waves of COVID.Therapeutic approach was different between the two waves in the intensive care unit (ICU). We aimed to compare the two different periods in terms of characteristics and outcomes and to evaluate risk factors associated with 60-day mortality in our overall cohort. Methods All consecutive patients with laboratory confirmed COVID-19 pneumonia and requiring oxygen support admitted in our ICU unit of University Hospital of Guadeloupe were prospectively included. Patients were treated during the first wave with a combination of Hydroxychloroquine and Azithromycin and during the second wave with dexamethasone and reinforced anticoagulation. Results In our cohort, 187 patients were included, 31 during the first one and 156 during the second. Patients were mostly male (69%) with a median age of 64years old. Patients tend to be younger during the second wave and body mass index was higher (respectively 31 vs 27kg/m2, p=0.01). Overall mortality at Day 60 was high (45%) and not different between the two waves. Among patients under mechanical ventilation risk factors associated with death in a multivariate analysis were a high number of comorbidities, a high level of SOFA score and the delay of invasive mechanical ventilation (IMV) onset after admission in ICU (OR=1.6 (95% CI 1.2 – 2.4). Conclusion Although therapeutics approach evolve, COVID-19 severe pneumonia is still associated with a high mortality rate in ICU.
A practical guide for the management of acute abdominal pain with fever in patients with autosomal dominant polycystic kidney disease
Jouret, François , Hogan, Marie C. , Hogan, Marie C , Chebib, Fouad T.

Mayo Clinic

Nephrology Dialysis Transplantation | February 10, 2021 | Volume: 37 | Issue: 8 | Pages: 1426-1428

10.1093/ndt/gfab040 | PMID 33570579 Get It

Contributions of cardiac dysfunction and volume status to central haemodynamics in chronic heart failure
Sorimachi, Hidemi, Grill, Diane E. , Miller, Wayne L. , Fischer, Karen, Fischer, Karen M. , Borlaug, Barry A.

Mayo Clinic

European Journal of Heart Failure | February 10, 2021 | Volume: 23 | Issue: 7 | Pages: 1097-1105

10.1002/ejhf.2121 | PMID 33565251 Get It

Abstract Aims Elevated cardiac filling pressures producing clinical congestion in heart failure (HF) patients may be secondary to intravascular volume expansion or abnormalities in cardiac diastolic properties. The objective of this study was to assess the extent to which measures of myocardial function and intravascular volume correlate with haemodynamic abnormalities in chronic HF. Methods and results Subjects underwent invasive haemodynamic assessment, measurement of total blood volume (TBV) using radiolabel indicator‐dilution methodology, and echocardiography to evaluate cardiac structure and function. Patients were divided into those with hypervolaemia (defined as TBV > +8% above referenced normal volume) and normal volume (‘euvolaemia’) (TBV ≤ + 8%). Of 66 patients, 39 (59%) were hypervolaemic and 27 (41%) normal TBV. Central venous pressure (CVP, P = 0.01) and pulmonary capillary wedge pressure (PCWP, P < 0.001) were higher in hypervolaemic compared with euvolaemic patients; however, 15% of hypervolaemic patients displayed normal pressures. Of euvolaemic patients, 70% displayed elevated CVP and 63% elevated PCWP. PCWP was moderately correlated with TBV (r = 0.42), left ventricular diastolic function (e′ velocity, r = −0.44), and left atrial strain (r = −0.47). In multivariable regression TBV, left ventricular e′, and left atrial strain were independently associated with PCWP (all P < 0.05). Conclusions While hypervolaemic patients displayed elevations in filling pressures, a substantial proportion (15%) had normal pressures, and of all subjects with elevated filling pressures nearly one third had normal TBVs. Importantly, of patients with normal volumes, a majority (>60%) display elevated filling pressures. Combined analysis of volume, pressure, and cardiac function may be helpful to guide comprehensive assessments of HF status.
Pathologic Quiz Case: An 83-Year-Old Woman With a Uterine Cervical Mass
Dimashkieh, Haytham, Khazai, Laila , Novak, Gregory D., Casey, Mary B., Dimashkieh, Haytham H

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 10, 2021 | Volume: 128 | Issue: 7 | Pages: 817-818

10.5858/2004-128-817-pqcayw | PMID 15214839 Get It

Respiratory Distress Caused by a Hydatid Cyst
Prasad, Anil , Seetharaman, M L

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 9, 2021 | Volume: 125 | Issue: 4 | Pages: 580-580

10.5858/2001-125-0580-rdcbah | PMID 11260647 Get It

TAR DNA-Binding Protein 43 Is Associated with Rate of Memory, Functional and Global Cognitive Decline in the Decade Prior to Death
Buciuc, Marina , Tosakulwong, Nirubol , Whitwell, Jennifer L. , Weigand, Stephen D. , Murray, Melissa E. , Reichard, R. Ross , Parisi, Joseph E., Petersen, Ronald C. , Josephs, Keith A. , Buciuc, Marina , Murray, Melissa E , Machulda, Mary M. , Dickson, Dennis W. , Boeve, Bradley F. , Knopman, David S.

Mayo Clinic

Journal of Alzheimer's Disease | February 9, 2021 | Volume: 80 | Issue: 2 | Pages: 683-693

10.3233/jad-201166 | PMID 33579840 Get It

Background: Transactive response DNA-binding protein of 43 kDa (TDP-43) is associated with memory impairment and overall cognitive decline. It is unclear how TDP-43 contributes to the rate of clinical decline. Objective: To determine whether cross-sectional and longitudinal cognitive and functional decline are associated with anatomical distribution of TDP-43 in the brain. Methods: Longitudinal clinical-neuropathologic autopsy cohort study of 385 initially cognitively normal/mildly impaired older adults prospectively followed until death. We investigated how TDP-43, amyloid-β (Aβ), tau neurofibrillary tangles (NFT), Lewy body disease (LBD), age, sex, and genetics are associated with clinical scores and rates of their longitudinal decline. Results: Of 385 participants, 260 (68%) had no TDP-43, 32 (8%) had TDP-43 limited to amygdala, and 93 (24%) had TDP-43 in the hippocampus and beyond. Higher TDP-43 and Braak NFT stages independently were associated with faster decline in global cognition, functional performance measured by Clinical Dementia Rating scale, and naming and episodic memory, whereas older age was associated with slower rate of cognitive, psychiatric, and functional decline. Cross-sectionally the following associations were found: higher TDP-43 and Braak NFT - worse performance; higher Aβ burden - worse global cognition, more behavioral changes, the latter also with higher LBD; older age - worse naming, lower frequency of behavioral changes; female sex - more impaired naming and better preserved episodic memory. There were no genetic associations. Conclusion: The association of TDP-43 distribution with decline in cognitive and functional performance suggests that TDP-43 is playing a role in the clinical progression to dementia. Further characterization of clinical features associated with TDP-43 can facilitate establishment of antemortem diagnosis.
Brain functions and cognition on transient insulin deprivation in type 1 diabetes
Creo, Ana L. , Cortes, Tiffany , Huebner, Andrea R., Dasari, Surendra , Tillema, Jan-Mendelt , Lteif, Aida, Klaus, Katherine A. , Ruegsegger, Gregory N. , Kudva, Yogish C. , Petersen, Ronald C. , Jo, Hang Joon , Tillema, Jan‐Mendelt , Port, John D. , Nair, K. Sreekumaran

Mayo Clinic

JCI Insight | February 9, 2021 | Volume: 6 | Issue: 5 | Pages: No page available

10.1172/jci.insight.144014 | PMID 33561011 Get It

BACKGROUND Type 1 diabetes (T1D) is a risk factor for dementia and structural brain changes. It remains to be determined whether transient insulin deprivation that frequently occurs in insulin-treated individuals with T1D alters brain function. METHODS We therefore performed functional and structural magnetic resonance imaging, magnetic resonance spectroscopy, and neuropsychological testing at baseline and following 5.4 ± 0.6 hours of insulin deprivation in 14 individuals with T1D and compared results with those from 14 age-, sex-, and BMI-matched nondiabetic (ND) participants with no interventions. RESULTS Insulin deprivation in T1D increased blood glucose, and β-hydroxybutyrate, while reducing bicarbonate levels. Participants with T1D showed lower baseline brain N-acetyl aspartate and myo-inositol levels but higher cortical fractional anisotropy, suggesting unhealthy neurons and brain microstructure. Although cognitive functions did not differ between participants with T1D and ND participants at baseline, significant changes in fine motor speed as well as attention and short-term memory occurred following insulin deprivation in participants with T1D. Insulin deprivation also reduced brain adenosine triphosphate levels and altered the phosphocreatine/adenosine triphosphate ratio. Baseline differences in functional connectivity in brain regions between participants with T1D and ND participants were noted, and on insulin deprivation further alterations in functional connectivity between regions, especially cortical and hippocampus-caudate regions, were observed. These alterations in functional connectivity correlated to brain metabolites and to changes in cognition. CONCLUSION Transient insulin deprivation therefore caused alterations in executive aspects of cognitive function concurrent with functional connectivity between memory regions and the sensory cortex. These findings have important clinical implications, as many patients with T1D inadvertently have periods of transient insulin deprivation. TRIAL REGISTRATION ClinicalTrials.gov NCT03392441. FUNDING Clinical and Translational Science Award (UL1 TR002377) from the National Center for Advancing Translational Science; NIH grants (R21 AG60139 and R01 AG62859); the Mayo Foundation.
Regenerative Medicine Lexicon
Terzic, André , Terzic, Andre

Mayo Clinic

Regenerative Medicine | February 9, 2021 | Volume: 15 | Issue: 12 | Pages: 2325-2328

10.2217/rme-2020-0194 | PMID 33560172 Get It